# NCT05227664 (NCT05227664)

> A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05227664
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Akeso
- Conditions: Metastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer
- Interventions: AK117; AK112; Nab paclitaxel; paclitaxel
- Enrollment: 120
- Primary outcome: Objective response rates (ORR)
- Primary outcome: Number of participants with adverse events (AEs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 3
- Bluesky threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05227664